Cargando…

Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library

Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat for effective treatment of several difficult-to-treat infections in humans. To identify potential new treatment options for MRSA infections, we screened a clinical compound library consisting of 1524 compounds using a grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Hongxia, Yee, Rebecca, Cui, Peng, Tian, Lili, Zhang, Shuo, Shi, Wanliang, Sullivan, David, Zhu, Bingdong, Zhang, Wenhong, Zhang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618001/
https://www.ncbi.nlm.nih.gov/pubmed/28930155
http://dx.doi.org/10.3390/pathogens6030044
_version_ 1783267088979197952
author Niu, Hongxia
Yee, Rebecca
Cui, Peng
Tian, Lili
Zhang, Shuo
Shi, Wanliang
Sullivan, David
Zhu, Bingdong
Zhang, Wenhong
Zhang, Ying
author_facet Niu, Hongxia
Yee, Rebecca
Cui, Peng
Tian, Lili
Zhang, Shuo
Shi, Wanliang
Sullivan, David
Zhu, Bingdong
Zhang, Wenhong
Zhang, Ying
author_sort Niu, Hongxia
collection PubMed
description Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat for effective treatment of several difficult-to-treat infections in humans. To identify potential new treatment options for MRSA infections, we screened a clinical compound library consisting of 1524 compounds using a growth inhibition assay in 96-well plates. We identified 34 agents which are either bacteriostatic or bactericidal against log-phase clinical MRSA strain USA300. Among them, 9 candidates (thonzonium, cetylpyridinium, trilocarban, benzododecinium, bithionol, brilliant green, chlorquinaldol, methylbenzethonium and green violet) are known antiseptics, 11 candidates are known antibiotics currently recommended for the treatment of MRSA. We identified 9 new drug candidates, 5 of which (thiostrepton, carbomycin, spiramycin, clofazimine and chloroxine) are antibiotics used for treating other infections than S. aureus infections; 4 of which (quinaldine blue, closantel, dithiazanine iodide and pyrvinium pamoate) are drugs used for treating parasitic diseases or cancer. We ranked these new drug candidates according to their MICs against the MRSA strain USA300. Our findings may have implications for more effective treatment of MRSA infections.
format Online
Article
Text
id pubmed-5618001
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56180012017-09-30 Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library Niu, Hongxia Yee, Rebecca Cui, Peng Tian, Lili Zhang, Shuo Shi, Wanliang Sullivan, David Zhu, Bingdong Zhang, Wenhong Zhang, Ying Pathogens Article Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat for effective treatment of several difficult-to-treat infections in humans. To identify potential new treatment options for MRSA infections, we screened a clinical compound library consisting of 1524 compounds using a growth inhibition assay in 96-well plates. We identified 34 agents which are either bacteriostatic or bactericidal against log-phase clinical MRSA strain USA300. Among them, 9 candidates (thonzonium, cetylpyridinium, trilocarban, benzododecinium, bithionol, brilliant green, chlorquinaldol, methylbenzethonium and green violet) are known antiseptics, 11 candidates are known antibiotics currently recommended for the treatment of MRSA. We identified 9 new drug candidates, 5 of which (thiostrepton, carbomycin, spiramycin, clofazimine and chloroxine) are antibiotics used for treating other infections than S. aureus infections; 4 of which (quinaldine blue, closantel, dithiazanine iodide and pyrvinium pamoate) are drugs used for treating parasitic diseases or cancer. We ranked these new drug candidates according to their MICs against the MRSA strain USA300. Our findings may have implications for more effective treatment of MRSA infections. MDPI 2017-09-20 /pmc/articles/PMC5618001/ /pubmed/28930155 http://dx.doi.org/10.3390/pathogens6030044 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Niu, Hongxia
Yee, Rebecca
Cui, Peng
Tian, Lili
Zhang, Shuo
Shi, Wanliang
Sullivan, David
Zhu, Bingdong
Zhang, Wenhong
Zhang, Ying
Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
title Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
title_full Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
title_fullStr Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
title_full_unstemmed Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
title_short Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
title_sort identification of agents active against methicillin-resistant staphylococcus aureus usa300 from a clinical compound library
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618001/
https://www.ncbi.nlm.nih.gov/pubmed/28930155
http://dx.doi.org/10.3390/pathogens6030044
work_keys_str_mv AT niuhongxia identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT yeerebecca identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT cuipeng identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT tianlili identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT zhangshuo identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT shiwanliang identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT sullivandavid identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT zhubingdong identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT zhangwenhong identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary
AT zhangying identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary